Copyright
©2013 Baishideng.
World J Virol. May 12, 2013; 2(2): 102-109
Published online May 12, 2013. doi: 10.5501/wjv.v2.i2.102
Published online May 12, 2013. doi: 10.5501/wjv.v2.i2.102
Virus | EBV | HHV-8 | HPV | HBV | HCV | HTLV-1 |
Associated tumor(s): viral protein(s) expressed | BL: EBNA-1 | KS: vFLIP, vCYC, LANA-1 | Anogenital, oral, skin and laryngeal cancers: E6, E7 | HCC: HBx | HCC: CP10, NS3, NS5 | ATL: tax |
NPC, TCL: EBNA1 + LMP1 | PEL, MCD: vFLIP, vCYC, LANA-1, LANA-2, vIL-6 | |||||
HL: EBNA1 + LMP1-2 | ||||||
PTLD: EBNA1-6 + LMP1-2 | ||||||
Persistency | Always | Always | 20% infected subjects | 90%-95% infected newborns | 70%-85% infected subjects | Always |
5% infected adults | ||||||
Period between infection and tumor onset | 10-20 yr | 10-20 yr | 5-20 yr | 10-30 yr | 10-30 yr | 20-30 yr |
- Citation: Avanzi S, Alvisi G, Ripalti A. How virus persistence can initiate the tumorigenesis process. World J Virol 2013; 2(2): 102-109
- URL: https://www.wjgnet.com/2220-3249/full/v2/i2/102.htm
- DOI: https://dx.doi.org/10.5501/wjv.v2.i2.102